Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 90/100

Well-established physiological role in hepatic coagulation factor carboxylation and bone mineralization.

Knowledge Graph:Vector: HeartIntercellular Signaling
Head-to-Head CompareAudit in Stack
Supplements & NutraceuticalsHeartSilver Tier85–94Moderate Confidence (Translational)⚖️ Scientific Consensus: Stable

Vitamin K1 (Phylloquinone)

Essential dietary Vitamin K form regulating hepatic clotting cascades and microvascular integrity.

90/100
High Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Well-established physiological role in hepatic coagulation factor carboxylation and bone mineralization.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:25694037

Menaquinone-7 Supplementation Improves Arterial Stiffness in Healthy Postmenopausal Women: A Double-Blind Randomised Clinical Trial

DOUBLE BLIND RCT • Sample: N = 244

“Carotid-Femoral Pulse Wave Velocity and Circulating dp-ucMGP: -50%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Neutral Pathway
0/ 100

No direct primary biochemical modulation of heart health; pathway is neutral for Vitamin K1 (Phylloquinone).

Brain Longevity & Cognition

Neutral Pathway
0/ 100

No direct primary biochemical modulation of brain longevity; pathway is neutral for Vitamin K1 (Phylloquinone).

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

No direct primary biochemical modulation of metabolic health; pathway is neutral for Vitamin K1 (Phylloquinone).

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cancer defense; pathway is neutral for Vitamin K1 (Phylloquinone).

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

No direct primary biochemical modulation of testosterone; pathway is neutral for Vitamin K1 (Phylloquinone).

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

No direct primary biochemical modulation of chronic inflammation; pathway is neutral for Vitamin K1 (Phylloquinone).

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

No direct primary biochemical modulation of bone density; pathway is neutral for Vitamin K1 (Phylloquinone).

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cellular longevity; pathway is neutral for Vitamin K1 (Phylloquinone).

Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Vascular Elastocalcinosis Inhibition & Arterial Elasticity Preservation
Secondary Clinical Endpoints:
Bone Mineralization AccelerationVertebral Fracture Risk ReductionDental Enamel Remineralization
LEVL Recommended Tracking Metrics:
Heart & Cardiovascular HealthBone Density & Skeletal Strengtharterial elasticity

Arterial & Bone Defense

95/99
Very High EffectGrade A (Thrombosis and Haemostasis 3-Year Human RCT)100-300 mcg daily with meals
3-Year Vitamin K2 Trial on Arterial StiffnessPMID: 25858202

Clinical Endpoint: Three years of daily Vitamin K2 (MK-7) supplementation significantly decreased arterial stiffness measured by pulse wave velocity.

arterial_&_bone_defense

Vascular Health

85/99
High EffectGrade B (Human Clinical Cohort)2-6 weeks
Phylloquinone Intake and Risk of Cardiovascular DiseasePMID: 34367980

Clinical Endpoint: Ensures carboxylation of vascular Gla proteins, preventing microvascular leakiness and calcification.

vascular_health

Bone Matrix Health

85/99
High EffectGrade B (Human Clinical Cohort)2-6 weeks
Vitamin K1 Supplementation Retards Bone Loss in Postmenopausal WomenPMID: 18926928

Clinical Endpoint: Carboxylates osteocalcin, increasing bone mineral density and reducing fracture incidence.

bone_matrix_health
Explainable Longevity Score Decomposition

Score Breakdown: 90 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1x
Evidence Strength88/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude96/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index84/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit84/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility88/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=244 pooled participants) across 88/100 evidence strength and 96/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Vitamin K1 (Phylloquinone) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
244
Avg RoB
1.3 / 5
Human Clinical (n=244)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.3

Menaquinone-7 Supplementation Improves Arterial Stiffness in Healthy Postmenopausal Women: A Double-Blind Randomised Clinical Trial

Knapen MH, et al.•Thrombosis and Haemostasis•2015•N = 244•156 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
Carotid-Femoral Pulse Wave Velocity and Circulating dp-ucMGP-50%
-50%p < 0.05
Clinical Takeaway:A 3-year randomized trial demonstrated that long-term Vitamin K2 intake substantially decreased uncarboxylated MGP and significantly improved arterial elasticity.
Independent Academic Research
PubMed: 25694037DOI
Chronological Evolution of Evidence

Vitamin K1 (Phylloquinone) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Vitamin K1 (Phylloquinone) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Warfarin / Coumadin anticoagulation therapy

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)